← Eichor
Study identifier: NCT03657745 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

Condition: Alzheimer Disease · Mild Cognitive Impairment · Dementia  ·  Sponsor: Alzheimer's Light LLC

PhaseN/A
Planned participants2000
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersYes

About this study

Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.

This description comes directly from the study's public registry record.

Talk to the study team

Andrey Vyshedskiy, Ph.D.  ·  (617) 433-7724  ·  vysha@bu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Andrey VyshedskiyMiami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03657745